<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Anxiolytics and Hypnotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i404.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i404.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i404.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i403.htm" title="Previous: Zidovudine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1114.htm" title="Next: Melatonin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i404">Anxiolytics and Hypnotics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Anxiolytics and Hypnotics</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i2.htm" name="_2">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm" name="_15">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm" name="_20">Alcohol</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with alcohol </td><td></td></tr><tr><td><a href="41001i26.htm" name="_26">Alpha-blockers</a></td><td>enhanced hypotensive and sedative effects when  anxiolytics and hypnotics given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i39.htm" name="_39">Anaesthetics, General</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with general anaesthetics </td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i107.htm" name="_107">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i241.htm" name="_241">Antidepressants, Tricyclic</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with tricyclics </td><td></td></tr><tr><td><a href="41001i252.htm" name="_252">Antidepressants, Tricyclic (related)</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with tricyclic-related antidepressants </td><td></td></tr><tr><td><a href="41001i303.htm" name="_303">Antihistamines</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i363.htm" name="_363">Antipsychotics</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with baclofen </td><td></td></tr><tr><td><a href="41001i440.htm" name="_440">Beta-blockers</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i482.htm" name="_482">Clonidine</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with clonidine </td><td></td></tr><tr><td><a href="41001i522.htm" name="_522">Diazoxide</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with diuretics </td><td></td></tr><tr><td><a href="41001i763.htm" name="_763">Hydralazine</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with hydralazine </td><td></td></tr><tr><td><a href="41001i607.htm">Lofexidine</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with lofexidine </td><td></td></tr><tr><td><a href="41001i611.htm" name="_611">Methyldopa</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm" name="_764">Minoxidil</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with minoxidil </td><td></td></tr><tr><td><a href="41001i823.htm">Mirtazapine</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with mirtazapine </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm" name="_631">Nitrates</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with nitrates </td><td></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with opioid analgesics </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  anxiolytics and hypnotics possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i765.htm" name="_765">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  anxiolytics and hypnotics given with sodium nitroprusside </td><td></td></tr><tr><td><a href="41001i805.htm">Tizanidine</a></td><td>increased sedative effect when  anxiolytics and hypnotics given with tizanidine </td><td></td></tr></tbody></table><p><b>Melatonin</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  melatonin increased by cimetidine </td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>plasma concentration of  melatonin increased by fluvoxamine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  melatonin increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr></tbody></table><p><b>Benzodiazepines</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  benzodiazepines inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>serious adverse events reported with concomitant use of  benzodiazepines and clozapine (causality not established)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td>metabolism of  benzodiazepines inhibited by disulfiram (increased sedative effects)</td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td>plasma concentration of some  benzodiazepines increased by fluvoxamine </td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td> benzodiazepines possibly antagonise effects of levodopa </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>sedative effects possibly increased when  benzodiazepines given with moxonidine </td><td></td></tr><tr><td><a href="41001i366.htm">Olanzapine</a></td><td class="cBV"><b>increased risk of hypotension, bradycardia and respiratory depression when <i>parenteral</i>  benzodiazepines given with <i>intramuscular</i> olanzapine </b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> benzodiazepines possibly increase or decrease plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  benzodiazepines possibly accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1067.htm">Sodium Oxybate</a></td><td class="cBV"><b> benzodiazepines enhance effects of sodium oxybate (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td>effects of  benzodiazepines possibly reduced by theophylline </td><td></td></tr></tbody></table><p><b>Alprazolam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i480.htm">Digoxin</a></td><td> alprazolam increases plasma concentration of digoxin (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td>plasma concentration of  alprazolam increased by fluoxetine </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> alprazolam possibly increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>increased risk of prolonged sedation when  alprazolam given with indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of  alprazolam increased by itraconazole </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  alprazolam increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  alprazolam possibly increased by ritonavir (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Chlordiazepoxide</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          but has no specific interaction information.
        </p><p><b>Clobazam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i1144.htm">Stiripentol</a></td><td>plasma concentration of  clobazam increased by stiripentol </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td> clobazam possibly increases plasma concentration of valproate </td><td></td></tr></tbody></table><p><b>Clonazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  clonazepam often reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>increased risk of neurotoxicity when  clonazepam given with lithium </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  clonazepam often reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  clonazepam often reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>increased risk of side-effects when  clonazepam given with valproate </td><td></td></tr></tbody></table><p><b>Diazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>











<tr><td><a href="41001i914.htm">Esomeprazole</a></td><td>metabolism of  diazepam possibly inhibited by esomeprazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  diazepam increased by fluconazole (risk of prolonged sedation)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>metabolism of  diazepam inhibited by isoniazid </td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  diazepam possibly increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td>metabolism of  diazepam possibly inhibited by omeprazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td> diazepam increases or decreases plasma concentration of phenytoin </td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td>plasma concentration of  diazepam possibly increased by progestogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  diazepam accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  diazepam possibly increased by ritonavir (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  diazepam possibly increased by valproate </td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  diazepam increased by voriconazole (risk of prolonged sedation)</b></td><td></td></tr></tbody></table><p><b>Flurazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  flurazepam possibly increased by ritonavir (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr></tbody></table><p><b>Loprazolam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          but has no specific interaction information.
        </p><p><b>Lorazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  lorazepam reduced by probenecid (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i286.htm">Valproate</a></td><td>plasma concentration of  lorazepam possibly increased by valproate </td><td></td></tr></tbody></table><p><b>Lormetazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          but has no specific interaction information.
        </p><p><b>Midazolam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




























<tr><td><a href="41001i1010.htm">Aprepitant</a></td><td>plasma concentration of  midazolam increased by aprepitant (risk of prolonged sedation)</td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by atazanavir—avoid concomitant use of <i>oral</i> midazolam</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td>plasma concentration of  midazolam possibly increased by atorvastatin </td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>plasma concentration of <i>oral</i>  midazolam increased by boceprevir—manufacturer of boceprevir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  midazolam reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>metabolism of  midazolam inhibited by clarithromycin (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i1072.htm">Deferasirox</a></td><td>plasma concentration of  midazolam possibly reduced by deferasirox </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>metabolism of  midazolam inhibited by diltiazem (increased plasma concentration  with increased sedation)</td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td class="cBV"><b>increased risk of prolonged sedation when  midazolam given with efavirenz—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>metabolism of  midazolam inhibited by erythromycin (increased plasma concentration  with increased sedation)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td>metabolism of  midazolam possibly inhibited by fentanyl </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by fluconazole (risk of prolonged sedation)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by fosamprenavir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of <i>oral</i>  midazolam possibly increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by indinavir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by itraconazole (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by ketoconazole (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i846.htm">Lercanidipine</a></td><td> midazolam increases absorption of lercanidipine </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by nelfinavir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td>plasma concentration of  midazolam increased by nilotinib </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by posaconazole (risk of prolonged sedation)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by ritonavir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by saquinavir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of <i>oral</i>  midazolam possibly reduced by St John's wort </td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  midazolam possibly increased by telaprevir (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>metabolism of  midazolam inhibited by telithromycin (increased plasma concentration  with increased sedation)</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>metabolism of  midazolam inhibited by verapamil (increased plasma concentration  with increased sedation)</td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  midazolam increased by voriconazole (risk of prolonged sedation)</b></td><td></td></tr></tbody></table><p><b>Nitrazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i663.htm">Probenecid</a></td><td>excretion of  nitrazepam possibly reduced by probenecid (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Oxazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          but has no specific interaction information.
        </p><p><b>Temazepam</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i523.htm">Disulfiram</a></td><td>increased risk of  temazepam toxicity when given with disulfiram </td><td></td></tr></tbody></table><p><b>Buspirone</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  buspirone increased by diltiazem (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  buspirone increased by erythromycin (reduce dose of buspirone)</td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>plasma concentration of  buspirone increased by grapefruit juice </td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td> buspirone increases plasma concentration of haloperidol </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of  buspirone increased by itraconazole (reduce dose of buspirone)</td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td>manufacturer of  buspirone advises avoid concomitant use with MAOIs </td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  buspirone possibly accelerated by rifampicin </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td>plasma concentration of  buspirone increased by ritonavir (increased risk of toxicity)</td><td></td></tr><tr><td><a href="41001i260.htm">Tranylcypromine</a></td><td>avoidance of  buspirone for 10 days after stopping tranylcypromine advised by manufacturer of tranylcypromine</td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  buspirone increased by verapamil (reduce dose of buspirone)</td><td></td></tr></tbody></table><p><b>Chloral</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i220.htm">Coumarins</a></td><td> chloral may transiently enhance anticoagulant effect of coumarins </td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i542.htm">Furosemide</a></td><td>administration of  chloral with <i>parenteral</i> furosemide may displace thyroid hormone from binding sites</td><td></td></tr></tbody></table><p><b>Clomethiazole</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  clomethiazole inhibited by cimetidine (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Meprobamate</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          but has no specific interaction information.
        </p><p><b>Zaleplon</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  zaleplon inhibited by cimetidine (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  zaleplon accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr></tbody></table><p><b>Zolpidem</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  zolpidem accelerated by rifampicin (reduced plasma concentration and reduced effect)</td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  zolpidem possibly increased by ritonavir (risk of extreme sedation and respiratory depression—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td>sedative effects possibly increased when  zolpidem given with sertraline </td><td></td></tr></tbody></table><p><b>Zopiclone</b> belongs to
      <b>Anxiolytics and Hypnotics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i169.htm">Erythromycin</a></td><td>metabolism of  zopiclone inhibited by erythromycin </td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  zopiclone significantly reduced by rifampicin </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1114.htm" title="Melatonin">Melatonin</a></li><li id="_41001i405"><a href="41001i405.htm" title="Benzodiazepines">Benzodiazepines</a></li><li><a href="41001i427.htm" title="Buspirone">Buspirone</a></li><li><a href="41001i422.htm" title="Chloral">Chloral</a></li><li><a href="41001i423.htm" title="Clomethiazole">Clomethiazole</a></li><li><a href="41001i428.htm" title="Meprobamate">Meprobamate</a></li><li><a href="41001i904.htm" title="Zaleplon">Zaleplon</a></li><li><a href="41001i425.htm" title="Zolpidem">Zolpidem</a></li><li><a href="41001i426.htm" title="Zopiclone">Zopiclone</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i403.htm">Previous: Zidovudine</a> | <a class="top" href="41001i404.htm#">Top</a> | <a accesskey="]" href="41001i1114.htm">Next: Melatonin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>